In Segment C, individuals will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will receive ABBV-744 and ruxolitinib. Participants will receive treatment until eventually disease progression or the participants are not able to tolerate the study drugs. - Participant consumed grapefruit or grapefruit solutions within three days just before https://eduardoyjufs.dailyhitblog.com/37488598/5-easy-facts-about-abbv-744-brd4-inhibitor-mechanism-of-action-described